Feedback / Questions
ABBV-157 - AbbVie, Inventiva
ABBV-157: Proof-of-concept data from P1 trial (NCT03922607) for moderate-to-severe psoriasis in Q1 2021
(AbbVie)
-
Dec 24, 2020 -
Corporate Presentation
P1 data
•
Psoriasis
https://inventivapharma.com/wp-content/uploads/2020/08/21-Inventiva-Presentation-ENG-021220.pdf
Dec 24, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious